Due to the rapid clearance of [18F]ALF-NOTA-FAPI-04 by the kidneys, along with its lower physiological uptake in normal organs and higher TBR, FAP-targeted radiopharmaceutical therapy (FAP-RPT) emerges as an effective method to precisely deliver radiation to FAP- and stroma-rich tumor lesions while minimizing damage to surrounding normal tissues [25]. This evidence concerns the gene FAP and neoplasm.